Emergent BioSolutions (EBS) Receives FDA Approval for BioThrax Treatment

Emergent BioSolutions Inc. (NYSE: EBS) has approved its supplemental Biologics License Application (sBLA) to change the administration schedule of BioThrax® (Anthrax Vaccine Adsorbed) to a three-dose primary series of intramuscular injections at 0, 1, and 6 months. The booster series consists of intramuscular injections at 12 and 18 months after initiation of the primary series, and at 1-year intervals thereafter for those who remain at risk. Individuals are not considered protected until they have completed the three-dose primary immunization series. BioThrax is the only FDA-licensed vaccine for pre-exposure protection of adults against anthrax disease.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• JPMorgan Reinstates Emergent BioSolutions (EBS) at Underweight
• INmune Bio files for EMA orphan drug status for its RDEB cell therapy
• Imunon to hold R&D Day on Sept. 23 focused on ovarian cancer trial